ESA hemoglobin normalization,
does it really help with Reduced cardiovascular events in nondialysis chronic kidney disease?
research showsThe grade is F with 12 points. CHOIR's prespecified primary efficacy composite occurred in 125/715 (17.5%) at the high target versus 97/717 (13.5%) at the low target, HR 1.34 (95% CI 1.03 to 1.74), P=0.03. The lower confidence bound exceeds one.
ads claimFull-author comparison shows Ajay K. Singh shared by CHOIR and TREAT and Kai-Uwe Eckardt shared by CREATE and TREAT; CHOIR and CREATE did not overlap. CHOIR was supported by Ortho Biotech, CREATE by F. Hoffmann-La Roche, and TREAT by Amgen. The agents differed, but each tested a normal or near-normal hemoglobin strategy in nondialysis CKD.
Useful facts when choosing a product
- CHOIR authors were Ajay K Singh, Lynda Szczech, Kezhen L Tang, Huiman Barnhart, Shelly Sapp, Marsha Wolfson, and Donal Reddan.
- CREATE authors were Tilman B Drüeke, Francesco Locatelli, Naomi Clyne, Kai-Uwe Eckardt, Iain C Macdougall, Dimitrios Tsakiris, Hans-Ulrich Burger, and Armin Scherhag.
- TREAT shared Singh with CHOIR and Eckardt with CREATE.
- Korean practice uses prescription ESAs but does not target normal hemoglobin; Korean guidance describes initiation around 9 to 10 g/dL and maintenance around 10 to 11.5 g/dL.
What the research actually shows
CREATE randomized 603 patients with hemoglobin 11.0 to 12.5 g/dL and eGFR 15 to 35 to targets of 13 to 15 or 10.5 to 11.5 g/dL and found no primary cardiovascular benefit. TREAT randomized 4,038 patients with type 2 diabetes, nondialysis CKD, and hemoglobin at most 11 g/dL to darbepoetin targeting about 13 g/dL or placebo with rescue below 9. The prespecified cardiovascular co-primary outcome was 632/2012 (31.4%) versus 602/2026 (29.7%), HR 1.05 (0.94 to 1.17), while prespecified fatal or nonfatal stroke was 101/2012 (5.0%) versus 53/2026 (2.6%), HR 1.92 (1.38 to 2.68).
Why this is classified as F (12)
Three large trials failed to reproduce cardiovascular benefit, and CHOIR's prespecified primary efficacy interval lay entirely in the harm direction, giving F with 12 points.
Counterpoint. ESAs can still be individualized to treat anemia and reduce transfusion needs; this verdict is limited to cardiovascular benefit from normalization.
Rejudgment record. Cross-check applied — CHOIR's prespecified primary efficacy composite significantly increased at the high target, while CREATE and TREAT failed to reproduce cardiovascular benefit
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | RX | Repeatedly refuted in the same indication |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E- | Harm increased in the trials |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (F).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced cardiovascular composite events | F | Three large trials did not reproduce benefit, and CHOIR showed an increase. |
| Reduced stroke | F | TREAT found an increase, 5.0% versus 2.6%. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Open-label randomized high- versus low-hemoglobin target trial | 717 | Supported by Ortho Biotech Clinical Affairs | Death, MI, HF hospitalization, or stroke composite; primary efficacy | 125/715 versus 97/717; HR 1.34 (1.03 to 1.74), P=0.03; median 16 months | Significant harm in primary endpoint |
| Study 2 | Open-label randomized normal- versus low-target trial | 603 | F. Hoffmann-La Roche | Eight-event cardiovascular composite; primary | 58 versus 47 events; lower versus normal target HR 0.78 (0.53 to 1.14), P=0.20 | Same-direction null repetition |
| Study 3 | Double-blind placebo and rescue-controlled trial | 2026 | Supported by Amgen | Death/CV composite and death/renal composite; co-primary | CV 31.4% versus 29.7%, HR 1.05 (0.94 to 1.17); stroke 5.0% versus 2.6%, HR 1.92 (1.38 to 2.68) | Large repeated null trial with prespecified stroke harm |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-07).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-07 · Corrections: none
Cite this verdict
[Chamgap] ESA hemoglobin normalization x cardiovascular events in nondialysis CKD — Evidence Grade F·12. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/esa-normal-hemoglobin-nondialysis-ckd-cardiovascular-events/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.